Results 61 to 70 of about 359,491 (304)

DNA ligase LigE increases bacterial transformation with damaged extracellular DNA

open access: yesFEBS Letters, EarlyView.
The DNA ligase LigE from the naturally competent Gram‐negative bacterium Neisseria gonorrhoaea increases transformation with cut extracellular DNA. This process is ATP‐dependent and relies on the catalytic activity of LigE; it also requires that LigE contains an intact periplasmic localisation sequence, indicating that ligE functions in the periplasm ...
Jolyn Pan   +4 more
wiley   +1 more source

Comparison of SR101-staining in different ages.

open access: yes, 2012
A–C: staining in the ventrolateral medulla (VLM) with 1 µM SR101 for 20 min and 10 min wash out. EGFP-fluorescence is not shown. The SR101 labeling was poor in all three tested ages.
Christian Schnell (117226)   +2 more
core   +1 more source

STAINING TOXOPLASMA GONDII WITH FLUORESCEIN-LABELLED ANTIBODY [PDF]

open access: yesThe Journal of Experimental Medicine, 1957
Antitoxoplasma globulin was labelled with fluorescein and was used to stain Toxoplasma gondii organisms in smears of peritoneal exudate. The evidence indicates that this staining was due to an antigen-antibody reaction at the cellular level. Methods are presented for handling the organisms so that they can be stained over a period of several months ...
openaire   +4 more sources

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

PVL staining of breast tumoral tissues.

open access: yes, 2015
A. A Breast tumor TMA (formalin-fixed) was stained and imaged as described in Fig 8A. Tumors were all positive with a vast majority of cancer cells stained. Labeling intensity was estimated on a scale ranging from 1 to 4.
Aymeric Audfray (447681)   +12 more
core   +1 more source

RNLS labeling in normal human pancreas.

open access: yes, 2021
Representative images of RNLS labeling detected by immunohistochemistry using the m28-RNLS antibody in the normal human pancreas from (A) a patient who had undergone Whipple procedure for duodenal adenoma with essentially no signal and (B) a patient who ...
Melinda Wang (1367463)   +12 more
core   +1 more source

Surface Characterization of Biomaterials by Immunogold Staining - Quantitative Analysis [PDF]

open access: yes, 1986
The labeling of target proteins by immunogold particles has been analyzed based on Einstein\u27s law of Brownian motion. The theory was confirmed from the experiments which employed antifibrinogen gold markers to label fibrinogen molecules adsorbed on ...
Simmons, Scott R.   +2 more
core   +1 more source

Interfacial polymerization for colorimetric labeling of protein expression in cells. [PDF]

open access: yesPLoS ONE, 2014
Determining the location of rare proteins in cells typically requires the use of on-sample amplification. Antibody based recognition and enzymatic amplification is used to produce large amounts of visible label at the site of protein expression, but ...
Jacob L Lilly   +5 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy